These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21858815)

  • 1. ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients.
    Tachezy M; Effenberger K; Zander H; Minner S; Gebauer F; Vashist YK; Sauter G; Pantel K; Izbicki JR; Bockhorn M
    Int J Cancer; 2012 Jul; 131(2):396-405. PubMed ID: 21858815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated leukocyte cell adhesion molecule (CD166)--its prognostic power for colorectal cancer patients.
    Tachezy M; Zander H; Gebauer F; Marx A; Kaifi JT; Izbicki JR; Bockhorn M
    J Surg Res; 2012 Sep; 177(1):e15-20. PubMed ID: 22482754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.
    Donizy P; Zietek M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
    Diagn Pathol; 2015 Jul; 10():86. PubMed ID: 26134500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Membranous expression of activated leukocyte cell adhesion molecule contributes to poor prognosis and malignant phenotypes of non-small-cell lung cancer.
    Ishiguro F; Murakami H; Mizuno T; Fujii M; Kondo Y; Usami N; Taniguchi T; Yokoi K; Osada H; Sekido Y
    J Surg Res; 2013 Jan; 179(1):24-32. PubMed ID: 22985775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients.
    Tachezy M; Zander H; Marx AH; Gebauer F; Rawnaq T; Kaifi JT; Sauter G; Izbicki JR; Bockhorn M
    J Surg Res; 2011 Oct; 170(2):226-32. PubMed ID: 21816425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum activated leukocyte cell adhesion molecule and intercellular adhesion molecule-1 in patients with gastric cancer: Can they be used as biomarkers?
    Erturk K; Tastekin D; Bilgin E; Serilmez M; Bozbey HU; Sakar B
    Biomed Pharmacother; 2016 Feb; 77():86-91. PubMed ID: 26796270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of activated leukocute cell adhesion molecule in gastric cancer is associated with advanced stages and poor prognosis and miR-9 deregulation.
    Ye M; Du YL; Nie YQ; Zhou ZW; Cao J; Li YF
    Mol Med Rep; 2015 Mar; 11(3):2004-12. PubMed ID: 25395097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator.
    King JA; Ofori-Acquah SF; Stevens T; Al-Mehdi AB; Fodstad O; Jiang WG
    Breast Cancer Res; 2004; 6(5):R478-87. PubMed ID: 15318930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.
    Hein S; Müller V; Köhler N; Wikman H; Krenkel S; Streichert T; Schweizer M; Riethdorf S; Assmann V; Ihnen M; Beck K; Issa R; Jänicke F; Pantel K; Milde-Langosch K
    Breast Cancer Res Treat; 2011 Sep; 129(2):347-60. PubMed ID: 20972617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma.
    Verma A; Shukla NK; Deo SV; Gupta SD; Ralhan R
    Oncology; 2005; 68(4-6):462-70. PubMed ID: 16024937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.
    Mezzanzanica D; Fabbi M; Bagnoli M; Staurengo S; Losa M; Balladore E; Alberti P; Lusa L; Ditto A; Ferrini S; Pierotti MA; Barbareschi M; Pilotti S; Canevari S
    Clin Cancer Res; 2008 Mar; 14(6):1726-33. PubMed ID: 18347173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer.
    Burkhardt M; Mayordomo E; Winzer KJ; Fritzsche F; Gansukh T; Pahl S; Weichert W; Denkert C; Guski H; Dietel M; Kristiansen G
    J Clin Pathol; 2006 Apr; 59(4):403-9. PubMed ID: 16484444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disseminated tumor cells in bone marrow and the natural course of resected esophageal cancer.
    Vashist YK; Effenberger KE; Vettorazzi E; Riethdorf S; Yekebas EF; Izbicki JR; Pantel K
    Ann Surg; 2012 Jun; 255(6):1105-12. PubMed ID: 22580852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS mutation associated with CD44/CD166 immunoexpression as predictors of worse outcome in metastatic colon cancer.
    Ribeiro KB; da Silva Zanetti J; Ribeiro-Silva A; Rapatoni L; de Oliveira HF; da Cunha Tirapelli DP; Garcia SB; Feres O; da Rocha JJ; Peria FM
    Cancer Biomark; 2016 Mar; 16(4):513-21. PubMed ID: 27062566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer.
    Ihnen M; Müller V; Wirtz RM; Schröder C; Krenkel S; Witzel I; Lisboa BW; Jänicke F; Milde-Langosch K
    Breast Cancer Res Treat; 2008 Dec; 112(3):419-27. PubMed ID: 18172759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Impact of Activated Leucocyte Cell Adhesion Molecule (ALCAM/CD166) in Infantile Neuroblastoma.
    Wachowiak R; Mayer S; Kaifi J; Gebauer F; Izbicki JR; Lacher M; Bockhorn M; Tachezy M
    Anticancer Res; 2016 Aug; 36(8):3991-5. PubMed ID: 27466504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALCAM is associated with chemoresistance and tumor cell adhesion in pancreatic cancer.
    Hong X; Michalski CW; Kong B; Zhang W; Raggi MC; Sauliunaite D; De Oliveira T; Friess H; Kleeff J
    J Surg Oncol; 2010 Jun; 101(7):564-9. PubMed ID: 20461761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy.
    Jezierska A; Matysiak W; Motyl T
    Med Sci Monit; 2006 Aug; 12(8):BR263-73. PubMed ID: 16865058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated leukocyte cell adhesion molecule is a marker for thyroid carcinoma aggressiveness and disease-free survival.
    Chaker S; Kak I; MacMillan C; Ralhan R; Walfish PG
    Thyroid; 2013 Feb; 23(2):201-8. PubMed ID: 23148625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated leukocyte cell-adhesion molecule (ALCAM) promotes malignant phenotypes of malignant mesothelioma.
    Ishiguro F; Murakami H; Mizuno T; Fujii M; Kondo Y; Usami N; Yokoi K; Osada H; Sekido Y
    J Thorac Oncol; 2012 May; 7(5):890-9. PubMed ID: 22722789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.